[Gene therapy of primary immunodeficiencies. Present and future].
Serrano
F
F
Departamento de Inmunología y Oncología, Centro Nacional de Biotecnología, C.S.I.C., Universidad Autónoma de Madrid.
Laín de Lera
T
T
González
M A
MA
García
M J
MJ
Abad
J L
JL
Bernad
A
A
D000243:Adenosine Deaminase / Q000172:deficiency / Q000235:genetics; D015815:Cell Adhesion Molecules / Q000235:genetics; D002478:Cells, Cultured / Q000637:transplantation; D002648:Child; D002985:Clinical Protocols; D005260:Female; D005544:Forecasting; D015316:Genetic Therapy / Q000266:history / Q000639:trends; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics; D006105:Granulomatous Disease, Chronic / Q000235:genetics / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D049673:History, 20th Century; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000235:genetics / Q000628:therapy*; D007223:Infant; D007231:Infant, Newborn; D007558:Italy; D053616:Janus Kinase 3; D008297:Male; D009316:National Institutes of Health (U.S.); D009426:Netherlands; D011505:Protein-Tyrosine Kinases / Q000172:deficiency / Q000235:genetics; D011683:Purine-Nucleoside Phosphorylase / Q000172:deficiency / Q000235:genetics; D012190:Retroviridae / Q000235:genetics; D016511:Severe Combined Immunodeficiency / Q000145:classification / Q000201:enzymology / Q000235:genetics / Q000628:therapy; D014162:Transfection; D016896:Treatment Outcome; D014481:United States; D051746:ZAP-70 Protein-Tyrosine Kinase
D015815:Cell Adhesion Molecules; D011683:Purine-Nucleoside Phosphorylase; D011505:Protein-Tyrosine Kinases; C507933:JAK3 protein, human; D053616:Janus Kinase 3; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human; D000243:Adenosine Deaminase
Terapia génica de inmunodeficiencias primarias. Presente y futuro.